Drugs / recombinant LH
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02201914 Background | Jan → Oct 2014 | — | Bioroma | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant LH | “patients receive clomiphene citrate 100 mg daily starting on day 2 for 5 days and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 5; Cetrorelix 0,25 mg...” NCT02201914 ↗ |
| Known as | LH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02201914 ↗ |
| Modality | Protein / enzyme biologic | “225 IU recombinant LH” NCT02201914 ↗ |